AbbVie Inc

Healthcare
$145.21
+0.07 (0.05%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Open PricePrev. CloseVolumeAvg. Volume
$144.58$145.143,2415,423,814

Fundamentals

Market Cap$256.67B
P/B Ratio16
P/E Ratio19.1
Enterprise Value$314.45B
Div. Yield4.08%
Book Value9.03
EPS(TTM)7.53
ROE86.00%
Understand Fundamentals

About the Company

AbbVie is a relatively new biopharmaceutical company established in 2013; prior to that, it had been under Abbott Laboratories, sharing its legacy and rich history. Within just a few years AbbVie Inc. has established a stronghold over the scientific industry. Based in Chicago, Illinois, it markets its products in the entire United States, Germany, France, Italy, Canada, Japan, Spain, Brazil, the United Kingdom and the Netherlands. AbbVie focuses on providing patients with transformational medicines and therapies that would benefit and improve their lives. It aims to discover more than just a cure for the numerous severe diseases rampant across the world. Taking up new challenges is the principal vision of AbbVie and it has employed about 47,000 individuals across the globe in its search of difficult-to-cure illnesses. In 2020, it actively partook to find the vaccine to combat the Covid-19 pandemic. It donated an amount of $35 million to aid Covid-19 relief across the world. Its contribution to the development of its community and the global society, in general, has been recognised by esteemed directories like DiversityInc Top 50 Companies for Philanthropy, Dow Jones Sustainability World Index, The Civic 50. AbbVie Inc. entered the American stock market around the same time it was formed, with an initial stock price of $34.40. The company witnessed its highest-ever stock price on 26th January 2018, when it reached $123.21. It develops medications and therapies for some of the most difficult to deal with diseases and physical ailments. Few of its world-renowned products include its biological therapies, medical inhibitors, medicine for treating adults with leukaemia or lymphoma, medication for respiratory diseases, pancreatic enzyme therapy, and an array of treatments for rare and critical illnesses. Few of its most notable products include Humira, Skyrizi, Rinvoq, etc. The global sales of Ibrutinib, one of AbbVie’s most noted products, was estimated to be worth approximately $5 billion in 2020 – reaching 5 times more than the estimated amount in 2016, contributing to the company’s performance in terms of revenue generation.;
OrganisationAbbVie Inc
IndustryDrug Manufacturers—General
HeadQuartersNorth Chicago, IL

Company Financials

*All values are in Million $
No Graph Data To Display
Quarterly
Yearly

Similar Stocks

COMPANYMARKET PRICECLOSE PRICEMARKET CAP
Want to invest in US Stocks?
Signup with Groww to get started
Login / Register
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 3.7.1
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI